CLAS.H — Claritas Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Claritas Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2016 December 31st | 2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12 | 4.92 | 4.59 | 26.1 | 3.28 |
| Operating Profit | -12 | -4.92 | -4.59 | -26.1 | -3.28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11.6 | -31.9 | 6.84 | -25.8 | -0.674 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.6 | -31.9 | 6.93 | -21.2 | 4.21 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.6 | -31.9 | 6.93 | -21.2 | 4.21 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.6 | -31.9 | 6.93 | -21.2 | 4.21 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.15 | -5.13 | 0.642 | 0.038 | 0.538 |